Lung Disease Clinical Trials

245 recruitingLast updated: June 18, 2026

There are 245 actively recruiting lung disease clinical trials across 60 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1. Top locations include New York, New York, United States, Philadelphia, Pennsylvania, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Lung Disease Trials at a Glance

245 actively recruiting trials for lung disease are listed on ClinicalTrialsFinder across 6 cities in 60 countries. The largest study group is Not Applicable with 64 trials, with the heaviest enrollment activity in New York, Philadelphia, and Houston. Lead sponsors running lung disease studies include Assistance Publique - Hôpitaux de Paris, Bastiaan Driehuys, and Boehringer Ingelheim.

Browse lung disease trials by phase

Treatments under study

About Lung Disease Clinical Trials

Looking for clinical trials for Lung Disease? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 245 trials

Recruiting
Phase 3

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.344 enrolled6 locationsNCT07285655
Recruiting

Study of Lung Proteins in Patients With Pneumonia

Pulmonary DiseasePneumoniaLung Disease
National Institutes of Health Clinical Center (CC)750 enrolled1 locationNCT00077909
Recruiting

Study of the Disease Process of Lymphangioleiomyomatosis

PneumothoraxLymphangioleiomyomatosisLung Disease+1 more
National Heart, Lung, and Blood Institute (NHLBI)2,000 enrolled1 locationNCT00001465
Recruiting
Phase 1Phase 2

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.118 enrolled22 locationsNCT07407933
Recruiting

GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation

end stage lung diseaseLung TransplantRejection
National Heart, Lung, and Blood Institute (NHLBI)100 enrolled1 locationNCT07516379
Recruiting
Not Applicable

Hypertonic Saline Inhalation for Nontuberculous Mycobacterial Lung Disease

BronchiectasisNontuberculous Mycobacterial Lung Disease
Taipei Veterans General Hospital, Taiwan262 enrolled1 locationNCT07647575
Recruiting
Phase 3

Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis

Interstitial Lung Disease With Systemic Sclerosis
University Hospital, Tours102 enrolled1 locationNCT06549231
Recruiting

Breathlessness Perceptions Within Respiratory Diseases

Chronic Obstructive Pulmonary Disease (COPD)BronchiectasisAsthma (Diagnosis)+2 more
University Hospitals, Leicester75 enrolled1 locationNCT07648082
Recruiting
Phase 2

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

Intraventricular hemorrhageChronic lung disease of prematurityBronchopulmonary Dysplasia+1 more
OHB Neonatology Ltd.338 enrolled72 locationsNCT03253263
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting
Phase 4

The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance

Mycobacterium Abscessus Lung Disease
National Taiwan University Hospital60 enrolled1 locationNCT07514364
Recruiting
Phase 2

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Lung DiseasesBronchiolitis Obliterans SyndromeChronic Graft Versus Host Disease+1 more
Dana-Farber Cancer Institute45 enrolled6 locationsNCT05922761
Recruiting
Not Applicable

Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia

Chronic Obstructive Pulmonary DiseaseInterstitial Lung DiseaseHypoxemia
State University of New York at Buffalo24 enrolled1 locationNCT07512687
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Interstitial Lung DiseasesFamilial Pulmonary FibrosisInterstitial Lung Abnormalities
Boehringer Ingelheim80 enrolled56 locationsNCT07201922
Recruiting

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Interstitial Lung DiseasePulmonary HypertensionPulmonary Hypertension Due to Lung Diseases and Hypoxia
United Therapeutics900 enrolled67 locationsNCT06388421
Recruiting
Phase 2

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Lung Disease (COLD)
Haisco Pharmaceutical Group Co., Ltd.50 enrolled1 locationNCT07140328
Recruiting

Validation of Soluble Programmed Death-1 in Predicting Progression of Nodular-bronchiectatic Form of Nontuberculous Mycobacterial Lung Disease: a Multi-Country Research

Nontuberculous Mycobacterial Lung Disease
National Taiwan University Hospital500 enrolled1 locationNCT05678166
Recruiting

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

SarcoidosisIdiopathic Pulmonary FibrosisInterstitial Lung Diseases+1 more
University of Chicago4,000 enrolled1 locationNCT00470327
Recruiting
Not Applicable

Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea

Chronic Heart Failure (CHF)DyspneaCancer (With or Without Metastasis)+2 more
University Hospital, Geneva82 enrolled1 locationNCT07173348
Recruiting
Phase 2

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Non-small Cell Lung CancerLung NeoplasmsCarcinoma+6 more
Pfizer120 enrolled3 locationsNCT07489066